25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BioPharma Credit PLC
Buy, Hold or Sell?

Let's analyze BioPharma Credit PLC together

I guess you are interested in BioPharma Credit PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BioPharma Credit PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BioPharma Credit PLC

I send you an email if I find something interesting about BioPharma Credit PLC.

1. Quick Overview

1.1. Quick analysis of BioPharma Credit PLC (30 sec.)










1.2. What can you expect buying and holding a share of BioPharma Credit PLC? (30 sec.)

How much money do you get?

How much money do you get?
$0.15
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$0.99
Expected worth in 1 year
$0.96
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
$0.12
Return On Investment
14.3%

For what price can you sell your share?

Current Price per Share
$0.87
Expected price per share
$0.85 - $0.914
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of BioPharma Credit PLC (5 min.)




Live pricePrice per Share (EOD)
$0.87
Intrinsic Value Per Share
$0.56 - $0.62
Total Value Per Share
$1.54 - $1.61

2.2. Growth of BioPharma Credit PLC (5 min.)




Is BioPharma Credit PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$1.2b$1.3b-$48.3m-3.8%

How much money is BioPharma Credit PLC making?

Current yearPrevious yearGrowGrow %
Making money$27.3m$371.5m-$344.2m-1,259.0%
Net Profit Margin78.2%302.1%--

How much money comes from the company's main activities?

2.3. Financial Health of BioPharma Credit PLC (5 min.)




2.4. Comparing to competitors in the Asset Management industry (5 min.)




  Industry Rankings (Asset Management)  


Richest
#139 / 723

Most Revenue
#263 / 723

Most Profit
#193 / 723

Most Efficient
#303 / 723
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of BioPharma Credit PLC?

Welcome investor! BioPharma Credit PLC's management wants to use your money to grow the business. In return you get a share of BioPharma Credit PLC.

First you should know what it really means to hold a share of BioPharma Credit PLC. And how you can make/lose money.

Speculation

The Price per Share of BioPharma Credit PLC is $0.868. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BioPharma Credit PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BioPharma Credit PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.99. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.04 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BioPharma Credit PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.033.3%0.022.5%0.033.1%0.022.4%0.022.3%
Usd Book Value Change Per Share0.000.0%-0.01-0.7%0.000.1%0.00-0.2%0.033.8%
Usd Dividend Per Share0.0910.0%0.044.2%0.022.0%0.033.1%0.022.7%
Usd Total Gains Per Share0.0910.0%0.033.6%0.022.1%0.022.9%0.066.5%
Usd Price Per Share0.84-0.85-0.93-0.94-0.98-
Price to Earnings Ratio7.29-11.06-8.78-12.34-14.49-
Price-to-Total Gains Ratio9.69--470.69--100.80--81.55--42.87-
Price to Book Ratio0.85-0.85-0.93-0.94-1.04-
Price-to-Total Gains Ratio9.69--470.69--100.80--81.55--42.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.868
Number of shares1152
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.040.03
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share0.030.02
Gains per Quarter (1152 shares)35.7328.70
Gains per Year (1152 shares)142.91114.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1170-27133124-9105
2340-54276248-19220
3510-81419373-28335
4680-108562497-37450
5850-135705621-47565
61020-162848745-56680
71189-189991869-66795
81359-2161134993-75910
91529-24312771118-841025
101699-27014201242-941140

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%30.00.00.0100.0%30.00.00.0100.0%
Book Value Change Per Share1.01.02.025.0%3.05.04.025.0%4.010.06.020.0%9.013.08.030.0%9.013.08.030.0%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%30.00.00.0100.0%30.00.00.0100.0%
Total Gains per Share3.01.00.075.0%10.02.00.083.3%18.02.00.090.0%27.03.00.090.0%27.03.00.090.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of BioPharma Credit PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0.0060%0.000-100%-0.0020%0.033-100%
Book Value Per Share--0.9861.007-2%0.998-1%1.004-2%0.966+2%
Current Ratio--21.49915.644+37%13.542+59%16.331+32%29.132-26%
Debt To Asset Ratio--0.0030.007-61%0.011-75%0.009-70%0.018-84%
Debt To Equity Ratio--0.0030.007-61%0.012-75%0.010-70%0.020-86%
Dividend Per Share--0.0870.037+135%0.018+393%0.027+222%0.023+271%
Eps--0.0290.022+33%0.027+9%0.021+39%0.020+48%
Free Cash Flow Per Share--0.0190.027-30%0.036-46%0.024-19%0.022-11%
Free Cash Flow To Equity Per Share---0.055-0.015-73%0.005-1176%-0.007-88%0.029-290%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.999+0%
Intrinsic Value_10Y_max--0.622--------
Intrinsic Value_10Y_min--0.558--------
Intrinsic Value_1Y_max--0.107--------
Intrinsic Value_1Y_min--0.105--------
Intrinsic Value_3Y_max--0.288--------
Intrinsic Value_3Y_min--0.275--------
Intrinsic Value_5Y_max--0.427--------
Intrinsic Value_5Y_min--0.399--------
Market Cap1033432078.336-1%1046705037.8401084378421.962-3%1245817213.350-16%1273407267.369-18%1299940602.696-19%
Net Profit Margin--0.9080.782+16%3.021-70%7.126-87%5.027-82%
Operating Margin--2.7231.236+120%0.453+501%0.402+578%0.452+503%
Operating Ratio--0.2460.419-41%0.169+45%0.285-14%0.248-1%
Pb Ratio0.881+3%0.8520.845+1%0.935-9%0.941-9%1.042-18%
Pe Ratio7.528+3%7.28511.059-34%8.782-17%12.339-41%14.487-50%
Price Per Share0.868+3%0.8400.851-1%0.933-10%0.944-11%0.981-14%
Price To Free Cash Flow Ratio11.351+3%10.9858.564+28%11.991-8%14.111-22%27.236-60%
Price To Total Gains Ratio10.015+3%9.692-470.687+4957%-100.800+1140%-81.552+941%-42.870+542%
Quick Ratio--21.46315.623+37%13.528+59%16.313+32%29.112-26%
Return On Assets--0.0290.021+36%0.273-89%0.312-91%0.214-86%
Return On Equity--0.0290.022+35%0.278-89%0.316-91%0.217-87%
Total Gains Per Share--0.0870.031+179%0.018+381%0.025+248%0.056+54%
Usd Book Value--1228074000.0001284467500.000-4%1332856000.000-8%1351546100.000-9%1281379600.000-4%
Usd Book Value Change Per Share----0.0060%0.000-100%-0.0020%0.033-100%
Usd Book Value Per Share--0.9861.007-2%0.998-1%1.004-2%0.966+2%
Usd Dividend Per Share--0.0870.037+135%0.018+393%0.027+222%0.023+271%
Usd Eps--0.0290.022+33%0.027+9%0.021+39%0.020+48%
Usd Free Cash Flow--23821500.00035104750.000-32%47983000.000-50%31866324.950-25%28805949.967-17%
Usd Free Cash Flow Per Share--0.0190.027-30%0.036-46%0.024-19%0.022-11%
Usd Free Cash Flow To Equity Per Share---0.055-0.015-73%0.005-1176%-0.007-88%0.029-290%
Usd Market Cap1033432078.336-1%1046705037.8401084378421.962-3%1245817213.350-16%1273407267.369-18%1299940602.696-19%
Usd Price Per Share0.868+3%0.8400.851-1%0.933-10%0.944-11%0.981-14%
Usd Profit--35919000.00027340250.000+31%371542569.250-90%431424280.300-92%295045053.533-88%
Usd Revenue--39572500.00034091500.000+16%73248625.000-46%46555975.000-15%39844758.333-1%
Usd Total Gains Per Share--0.0870.031+179%0.018+381%0.025+248%0.056+54%
 EOD+2 -6MRQTTM+20 -13YOY+16 -195Y+17 -1610Y+18 -18

3.3 Fundamental Score

Let's check the fundamental score of BioPharma Credit PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-157.528
Price to Book Ratio (EOD)Between0-10.881
Net Profit Margin (MRQ)Greater than00.908
Operating Margin (MRQ)Greater than02.723
Quick Ratio (MRQ)Greater than121.463
Current Ratio (MRQ)Greater than121.499
Debt to Asset Ratio (MRQ)Less than10.003
Debt to Equity Ratio (MRQ)Less than10.003
Return on Equity (MRQ)Greater than0.150.029
Return on Assets (MRQ)Greater than0.050.029
Total8/10 (80.0%)

3.4 Technical Score

Let's check the technical score of BioPharma Credit PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.018
Ma 20Greater thanMa 500.862
Ma 50Greater thanMa 1000.870
Ma 100Greater thanMa 2000.863
OpenGreater thanClose0.860
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About BioPharma Credit PLC

BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in London, the United Kingdom.

Fundamental data was last updated by Penke on 2024-11-02 02:14:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit BioPharma Credit PLC earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare BioPharma Credit PLC to the Asset Management industry mean.
  • A Net Profit Margin of 90.8% means that $0.91 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioPharma Credit PLC:

  • The MRQ is 90.8%. The company is making a huge profit. +2
  • The TTM is 78.2%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ90.8%TTM78.2%+12.6%
TTM78.2%YOY302.1%-223.9%
TTM78.2%5Y712.6%-634.4%
5Y712.6%10Y502.7%+209.9%
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
MRQ90.8%55.3%+35.5%
TTM78.2%54.0%+24.2%
YOY302.1%62.1%+240.0%
5Y712.6%56.4%+656.2%
10Y502.7%53.8%+448.9%
4.3.1.2. Return on Assets

Shows how efficient BioPharma Credit PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BioPharma Credit PLC to the Asset Management industry mean.
  • 2.9% Return on Assets means that BioPharma Credit PLC generated $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioPharma Credit PLC:

  • The MRQ is 2.9%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.1%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.9%TTM2.1%+0.8%
TTM2.1%YOY27.3%-25.1%
TTM2.1%5Y31.2%-29.1%
5Y31.2%10Y21.4%+9.8%
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9%1.3%+1.6%
TTM2.1%1.5%+0.6%
YOY27.3%0.8%+26.5%
5Y31.2%1.7%+29.5%
10Y21.4%1.8%+19.6%
4.3.1.3. Return on Equity

Shows how efficient BioPharma Credit PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BioPharma Credit PLC to the Asset Management industry mean.
  • 2.9% Return on Equity means BioPharma Credit PLC generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioPharma Credit PLC:

  • The MRQ is 2.9%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.9%TTM2.2%+0.8%
TTM2.2%YOY27.8%-25.6%
TTM2.2%5Y31.6%-29.4%
5Y31.6%10Y21.7%+9.9%
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9%2.4%+0.5%
TTM2.2%2.7%-0.5%
YOY27.8%1.7%+26.1%
5Y31.6%2.6%+29.0%
10Y21.7%3.0%+18.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of BioPharma Credit PLC.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient BioPharma Credit PLC is operating .

  • Measures how much profit BioPharma Credit PLC makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BioPharma Credit PLC to the Asset Management industry mean.
  • An Operating Margin of 272.3% means the company generated $2.72  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioPharma Credit PLC:

  • The MRQ is 272.3%. The company is operating very efficient. +2
  • The TTM is 123.6%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ272.3%TTM123.6%+148.7%
TTM123.6%YOY45.3%+78.3%
TTM123.6%5Y40.2%+83.4%
5Y40.2%10Y45.2%-5.0%
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
MRQ272.3%84.7%+187.6%
TTM123.6%71.2%+52.4%
YOY45.3%50.2%-4.9%
5Y40.2%46.2%-6.0%
10Y45.2%47.7%-2.5%
4.3.2.2. Operating Ratio

Measures how efficient BioPharma Credit PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Asset Management industry mean).
  • An Operation Ratio of 0.25 means that the operating costs are $0.25 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of BioPharma Credit PLC:

  • The MRQ is 0.246. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.419. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.246TTM0.419-0.173
TTM0.419YOY0.169+0.250
TTM0.4195Y0.285+0.134
5Y0.28510Y0.248+0.037
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2460.417-0.171
TTM0.4190.460-0.041
YOY0.1690.595-0.426
5Y0.2850.550-0.265
10Y0.2480.552-0.304
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of BioPharma Credit PLC.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if BioPharma Credit PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Asset Management industry mean).
  • A Current Ratio of 21.50 means the company has $21.50 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of BioPharma Credit PLC:

  • The MRQ is 21.499. The company is very able to pay all its short-term debts. +2
  • The TTM is 15.644. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ21.499TTM15.644+5.855
TTM15.644YOY13.542+2.102
TTM15.6445Y16.331-0.687
5Y16.33110Y29.132-12.801
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
MRQ21.4992.809+18.690
TTM15.6443.161+12.483
YOY13.5423.709+9.833
5Y16.3315.075+11.256
10Y29.1327.346+21.786
4.4.3.2. Quick Ratio

Measures if BioPharma Credit PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BioPharma Credit PLC to the Asset Management industry mean.
  • A Quick Ratio of 21.46 means the company can pay off $21.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioPharma Credit PLC:

  • The MRQ is 21.463. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.623. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ21.463TTM15.623+5.839
TTM15.623YOY13.528+2.095
TTM15.6235Y16.313-0.689
5Y16.31310Y29.112-12.800
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
MRQ21.4632.976+18.487
TTM15.6233.381+12.242
YOY13.5284.400+9.128
5Y16.3136.457+9.856
10Y29.1128.616+20.496
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of BioPharma Credit PLC.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of BioPharma Credit PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BioPharma Credit PLC to Asset Management industry mean.
  • A Debt to Asset Ratio of 0.00 means that BioPharma Credit PLC assets are financed with 0.3% credit (debt) and the remaining percentage (100% - 0.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioPharma Credit PLC:

  • The MRQ is 0.003. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.007. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.003TTM0.007-0.004
TTM0.007YOY0.011-0.004
TTM0.0075Y0.009-0.002
5Y0.00910Y0.018-0.009
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0030.174-0.171
TTM0.0070.166-0.159
YOY0.0110.183-0.172
5Y0.0090.174-0.165
10Y0.0180.177-0.159
4.5.4.2. Debt to Equity Ratio

Measures if BioPharma Credit PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BioPharma Credit PLC to the Asset Management industry mean.
  • A Debt to Equity ratio of 0.3% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioPharma Credit PLC:

  • The MRQ is 0.003. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.007. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.003TTM0.007-0.004
TTM0.007YOY0.012-0.004
TTM0.0075Y0.010-0.002
5Y0.01010Y0.020-0.010
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0030.201-0.198
TTM0.0070.196-0.189
YOY0.0120.224-0.212
5Y0.0100.238-0.228
10Y0.0200.246-0.226
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings BioPharma Credit PLC generates.

  • Above 15 is considered overpriced but always compare BioPharma Credit PLC to the Asset Management industry mean.
  • A PE ratio of 7.29 means the investor is paying $7.29 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioPharma Credit PLC:

  • The EOD is 7.528. Based on the earnings, the company is underpriced. +1
  • The MRQ is 7.285. Based on the earnings, the company is cheap. +2
  • The TTM is 11.059. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD7.528MRQ7.285+0.243
MRQ7.285TTM11.059-3.774
TTM11.059YOY8.782+2.276
TTM11.0595Y12.339-1.280
5Y12.33910Y14.487-2.149
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
EOD7.5287.447+0.081
MRQ7.2856.786+0.499
TTM11.0596.842+4.217
YOY8.7824.322+4.460
5Y12.3395.512+6.827
10Y14.4876.977+7.510
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioPharma Credit PLC:

  • The EOD is 11.351. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 10.985. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 8.564. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD11.351MRQ10.985+0.366
MRQ10.985TTM8.564+2.421
TTM8.564YOY11.991-3.427
TTM8.5645Y14.111-5.547
5Y14.11110Y27.236-13.125
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
EOD11.3515.724+5.627
MRQ10.9855.446+5.539
TTM8.5644.714+3.850
YOY11.9913.116+8.875
5Y14.1113.642+10.469
10Y27.2362.975+24.261
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of BioPharma Credit PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Asset Management industry mean).
  • A PB ratio of 0.85 means the investor is paying $0.85 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of BioPharma Credit PLC:

  • The EOD is 0.881. Based on the equity, the company is cheap. +2
  • The MRQ is 0.852. Based on the equity, the company is cheap. +2
  • The TTM is 0.845. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.881MRQ0.852+0.028
MRQ0.852TTM0.845+0.007
TTM0.845YOY0.935-0.089
TTM0.8455Y0.941-0.096
5Y0.94110Y1.042-0.102
Compared to industry (Asset Management)
PeriodCompanyIndustry (mean)+/- 
EOD0.8810.942-0.061
MRQ0.8520.916-0.064
TTM0.8450.913-0.068
YOY0.9350.932+0.003
5Y0.9411.008-0.067
10Y1.0421.171-0.129
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets1,231,609
Total Liabilities3,535
Total Stockholder Equity1,228,074
 As reported
Total Liabilities 3,535
Total Stockholder Equity+ 1,228,074
Total Assets = 1,231,609

Assets

Total Assets1,231,609
Total Current Assets74,151
Long-term Assets1,157,458
Total Current Assets
Cash And Cash Equivalents 37,144
Net Receivables 36,881
Other Current Assets 126
Total Current Assets  (as reported)74,151
Total Current Assets  (calculated)74,151
+/-0
Long-term Assets
Long-term Assets  (as reported)1,157,458
Long-term Assets  (calculated)0
+/- 1,157,458

Liabilities & Shareholders' Equity

Total Current Liabilities3,449
Long-term Liabilities86
Total Stockholder Equity1,228,074
Total Current Liabilities
Total Current Liabilities  (as reported)3,449
Total Current Liabilities  (calculated)0
+/- 3,449
Long-term Liabilities
Long-term Liabilities  (as reported)86
Long-term Liabilities  (calculated)0
+/- 86
Total Stockholder Equity
Common Stock13,739
Retained Earnings 607,210
Accumulated Other Comprehensive Income 552,011
Other Stockholders Equity 55,114
Total Stockholder Equity (as reported)1,228,074
Total Stockholder Equity (calculated)1,228,074
+/-0
Other
Cash and Short Term Investments 37,144
Common Stock Shares Outstanding 1,246,077
Liabilities and Stockholders Equity 1,231,609
Net Debt -37,144
Net Working Capital 70,702



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312019-01-312018-12-312018-09-302018-06-302018-03-312018-01-312017-12-312017-06-30
> Total Assets 
759,387
925,490
0
1,082,551
1,082,551
1,393,273
1,393,273
0
1,421,128
1,421,128
1,428,971
1,428,971
1,410,365
1,410,365
1,388,308
1,388,308
1,374,912
1,374,912
1,370,617
1,370,617
1,388,209
1,388,209
1,364,016
1,364,016
1,332,938
1,332,938
1,356,732
1,356,732
1,231,609
1,231,609
1,231,6091,231,6091,356,7321,356,7321,332,9381,332,9381,364,0161,364,0161,388,2091,388,2091,370,6171,370,6171,374,9121,374,9121,388,3081,388,3081,410,3651,410,3651,428,9711,428,9711,421,1281,421,12801,393,2731,393,2731,082,5511,082,5510925,490759,387
   > Total Current Assets 
483,322
355,860
0
154,707
154,707
385,020
386,008
0
620,129
624,178
312,844
312,844
64,281
64,011
193,477
193,477
148,854
148,854
104,719
104,719
56,319
56,319
140,365
140,365
107,455
107,455
155,370
155,370
74,151
74,151
74,15174,151155,370155,370107,455107,455140,365140,36556,31956,319104,719104,719148,854148,854193,477193,47764,01164,281312,844312,844624,178620,1290386,008385,020154,707154,7070355,860483,322
       Cash And Cash Equivalents 
478,794
350,822
0
149,194
149,194
363,572
363,572
0
612,888
612,888
296,638
296,638
61,058
60,788
193,269
193,269
122,478
122,478
94,709
94,709
10,436
10,436
120,527
120,527
67,877
67,877
135,053
135,053
37,144
37,144
37,14437,144135,053135,05367,87767,877120,527120,52710,43610,43694,70994,709122,478122,478193,269193,26960,78861,058296,638296,638612,888612,8880363,572363,572149,194149,1940350,822478,794
       Net Receivables 
4,528
5,038
0
4,448
5,513
20,637
22,436
0
6,946
11,290
15,871
16,206
2,950
3,223
3
208
26,072
26,376
9,594
10,010
45,693
45,883
19,727
19,838
39,447
39,447
20,226
20,226
36,881
36,881
36,88136,88120,22620,22639,44739,44719,83819,72745,88345,69310,0109,59426,37626,07220833,2232,95016,20615,87111,2906,946022,43620,6375,5134,44805,0384,528
       Other Current Assets 
0
0
0
1,065
1,065
811
811
0
295
295
335
335
273
-64,281
205
-193,477
304
-148,854
416
-104,719
190
190
111
111
131
131
91
91
126
126
1261269191131131111111190190-104,719416-148,854304-193,477205-64,28127333533529529508118111,0651,065000
   > Long-term Assets 
276,065
569,630
0
927,844
927,844
1,008,253
1,007,265
0
800,999
796,950
1,116,127
1,116,127
1,346,084
1,346,084
1,194,831
1,194,831
1,226,058
1,226,058
1,265,898
1,265,898
1,331,890
1,331,890
1,223,651
1,223,651
1,225,483
1,225,483
1,201,362
1,201,362
1,157,458
1,157,458
1,157,4581,157,4581,201,3621,201,3621,225,4831,225,4831,223,6511,223,6511,331,8901,331,8901,265,8981,265,8981,226,0581,226,0581,194,8311,194,8311,346,0841,346,0841,116,1271,116,127796,950800,99901,007,2651,008,253927,844927,8440569,630276,065
       Long Term Investments 
276,065
0
0
927,844
927,844
1,007,265
1,007,265
0
796,950
796,950
0
1,116,127
0
1,346,084
0
1,194,831
0
1,226,058
0
1,265,898
0
1,331,890
0
1,223,651
0
0
0
0
0
0
0000001,223,65101,331,89001,265,89801,226,05801,194,83101,346,08401,116,1270796,950796,95001,007,2651,007,265927,844927,84400276,065
       Other Assets 
0
0
0
0
0
988
988
0
4,049
4,049
0
1,428,971
0
270
0
1,388,308
0
1,374,912
0
1,370,617
0
1,388,209
0
0
0
0
0
0
0
0
000000001,388,20901,370,61701,374,91201,388,308027001,428,97104,0494,049098898800000
> Total Liabilities 
5,657
2,916
0
164,014
164,014
5,457
13,251
0
3,904
11,698
24,504
25,235
31,373
31,937
9,393
9,393
3,822
3,822
6,342
6,900
4,002
4,413
26,301
26,301
4,941
4,941
15,871
15,871
3,535
3,535
3,5353,53515,87115,8714,9414,94126,30126,3014,4134,0026,9006,3423,8223,8229,3939,39331,93731,37325,23524,50411,6983,904013,2515,457164,014164,01402,9165,657
   > Total Current Liabilities 
5,657
0
0
164,014
164,014
5,457
5,457
0
3,904
3,904
24,504
24,504
31,373
31,373
9,393
9,393
3,822
3,822
6,342
6,342
4,002
4,002
26,301
26,301
4,941
4,941
15,871
15,871
3,449
3,449
3,4493,44915,87115,8714,9414,94126,30126,3014,0024,0026,3426,3423,8223,8229,3939,39331,37331,37324,50424,5043,9043,90405,4575,457164,014164,014005,657
       Accounts payable 
5,657
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,822
3,822
0
6,342
0
0
0
0
0
0
0
0
0
0
00000000006,34203,8223,8220000000000000005,657
       Other Current Liabilities 
0
0
0
164,014
164,014
5,457
5,457
0
3,904
3,904
24,504
24,504
31,373
31,373
9,393
9,393
3,822
3,822
6,342
-6,342
4,002
4,002
26,301
26,301
4,941
4,941
15,871
15,871
0
0
0015,87115,8714,9414,94126,30126,3014,0024,002-6,3426,3423,8223,8229,3939,39331,37331,37324,50424,5043,9043,90405,4575,457164,014164,014000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
31,937
0
9,393
0
3,822
0
6,342
0
4,002
0
26,563
0
0
0
0
86
86
8686000026,56304,00206,34203,82209,393031,9370000000000000
       Other Liabilities 
0
2,916
0
164,014
164,014
7,794
7,794
0
7,794
7,794
731
731
564
564
0
0
0
0
558
558
411
411
0
0
116
116
0
0
0
0
00001161160041141155855800005645647317317,7947,79407,7947,794164,014164,01402,9160
> Total Stockholder Equity
753,730
922,574
0
918,537
918,537
1,380,022
1,380,022
0
1,409,430
1,409,430
1,403,736
1,403,736
1,378,428
1,378,428
1,378,915
1,378,915
1,371,090
1,371,090
1,363,717
1,363,717
1,383,796
1,383,796
1,337,453
1,337,453
1,327,881
1,327,881
1,340,861
1,340,861
1,228,074
1,228,074
1,228,0741,228,0741,340,8611,340,8611,327,8811,327,8811,337,4531,337,4531,383,7961,383,7961,363,7171,363,7171,371,0901,371,0901,378,9151,378,9151,378,4281,378,4281,403,7361,403,7361,409,4301,409,43001,380,0221,380,022918,537918,5370922,574753,730
   Common Stock
7,619
9,143
0
9,143
9,143
13,739
13,739
0
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,739
13,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,73913,739013,73913,7399,1439,14309,1437,619
   Retained Earnings 
746,111
0
0
759,017
759,017
759,158
759,158
0
788,566
788,566
782,872
782,872
757,564
14,894
758,051
7,545
750,226
24,683
742,853
20,371
762,932
762,932
716,589
716,589
707,017
707,017
719,997
719,997
607,210
607,210
607,210607,210719,997719,997707,017707,017716,589716,589762,932762,93220,371742,85324,683750,2267,545758,05114,894757,564782,872782,872788,566788,5660759,158759,158759,017759,01700746,111
   Capital Surplus 
0
0
0
0
0
0
0
0
0
607,125
0
607,125
0
607,125
0
607,125
0
607,125
0
0
0
0
0
0
0
0
0
0
0
0
000000000000607,1250607,1250607,1250607,1250607,125000000000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
913,431
0
150,377
150,377
607,125
607,125
0
607,125
607,125
607,125
607,125
607,125
607,125
607,125
607,125
607,125
607,125
607,125
607,125
607,125
-118,739
607,125
607,125
607,125
607,125
607,125
607,125
607,125
55,114
55,114607,125607,125607,125607,125607,125607,125607,125-118,739607,125607,125607,125607,125607,125607,125607,125607,125607,125607,125607,125607,125607,1250607,125607,125150,377150,3770913,4310



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue110,487
Cost of Revenue-25,243
Gross Profit85,24485,244
 
Operating Income (+$)
Gross Profit85,244
Operating Expense-2,037
Operating Income108,45083,207
 
Operating Expense (+$)
Research Development0
Selling General Administrative1,861
Selling And Marketing Expenses175
Operating Expense2,0372,036
 
Net Interest Income (+$)
Interest Income4,324
Interest Expense-0
Other Finance Cost-0
Net Interest Income4,324
 
Pretax Income (+$)
Operating Income108,450
Net Interest Income4,324
Other Non-Operating Income Expenses0
Income Before Tax (EBT)108,450108,457
EBIT - interestExpense = 216,907
216,900
108,450
Interest Expense0
Earnings Before Interest and Taxes (EBIT)216,907108,450
Earnings Before Interest and Taxes (EBITDA)108,450
 
After tax Income (+$)
Income Before Tax108,450
Tax Provision-0
Net Income From Continuing Ops108,450108,450
Net Income108,450
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,037
Total Other Income/Expenses Net-7-4,324
 

Technical Analysis of BioPharma Credit PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of BioPharma Credit PLC. The general trend of BioPharma Credit PLC is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine BioPharma Credit PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioPharma Credit PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.88 < 0.908 < 0.914.

The bearish price targets are: 0.85 > 0.85 > 0.85.

Tweet this
BioPharma Credit PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioPharma Credit PLC. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioPharma Credit PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioPharma Credit PLC. The current macd is -0.00081297.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the BioPharma Credit PLC price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for BioPharma Credit PLC. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the BioPharma Credit PLC price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
BioPharma Credit PLC Daily Moving Average Convergence/Divergence (MACD) ChartBioPharma Credit PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioPharma Credit PLC. The current adx is 11.16.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell BioPharma Credit PLC shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
BioPharma Credit PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioPharma Credit PLC. The current sar is 0.8472672.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
BioPharma Credit PLC Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioPharma Credit PLC. The current rsi is 51.02. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
BioPharma Credit PLC Daily Relative Strength Index (RSI) ChartBioPharma Credit PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioPharma Credit PLC. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the BioPharma Credit PLC price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
BioPharma Credit PLC Daily Stochastic Oscillator ChartBioPharma Credit PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioPharma Credit PLC. The current cci is 32.22.

BioPharma Credit PLC Daily Commodity Channel Index (CCI) ChartBioPharma Credit PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioPharma Credit PLC. The current cmo is 5.96272331.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
BioPharma Credit PLC Daily Chande Momentum Oscillator (CMO) ChartBioPharma Credit PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioPharma Credit PLC. The current willr is -35.29411765.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that BioPharma Credit PLC is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BioPharma Credit PLC Daily Williams %R ChartBioPharma Credit PLC Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BioPharma Credit PLC.

BioPharma Credit PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioPharma Credit PLC. The current atr is 0.01729457.

BioPharma Credit PLC Daily Average True Range (ATR) ChartBioPharma Credit PLC Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioPharma Credit PLC. The current obv is -27,631,028.

BioPharma Credit PLC Daily On-Balance Volume (OBV) ChartBioPharma Credit PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioPharma Credit PLC. The current mfi is 67.33.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
BioPharma Credit PLC Daily Money Flow Index (MFI) ChartBioPharma Credit PLC Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioPharma Credit PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-03ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-31WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-13STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

BioPharma Credit PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioPharma Credit PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.018
Ma 20Greater thanMa 500.862
Ma 50Greater thanMa 1000.870
Ma 100Greater thanMa 2000.863
OpenGreater thanClose0.860
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of BioPharma Credit PLC with someone you think should read this too:
  • Are you bullish or bearish on BioPharma Credit PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about BioPharma Credit PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioPharma Credit PLC

I send you an email if I find something interesting about BioPharma Credit PLC.


Comments

How you think about this?

Leave a comment

Stay informed about BioPharma Credit PLC.

Receive notifications about BioPharma Credit PLC in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.